Harmony Biosciences Holdings, Inc.
HRMY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $3 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $3 | $2 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 22.8% | 32.9% | 43.4% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 78.1% | 79.2% | 80.9% | 81.8% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 32.7% | 38.1% | 33.5% | 26.3% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 20.4% | 22.1% | 41.4% | 11.3% |
| EPS Diluted | 2.51 | 2.13 | 2.97 | 0.58 |
| % Growth | 17.8% | -28.3% | 412.1% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |